Athenex, Inc.

Informe acción OTCPK:ATNX.Q

Capitalización de mercado: US$131.7k

Athenex Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Athenex's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 11.2% per year.

Información clave

-7.6%

Tasa de crecimiento de los beneficios

9.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresos11.2%
Rentabilidad financieran/a
Margen neto-95.3%
Última actualización de beneficios31 Dec 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Athenex prices $30M in stock and warrants offering

Aug 11

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Aug 05

Athenex GAAP EPS, revenue misses estimates

Jul 28

Athenex to sell its China API business for $19M

Jul 11

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Aug 31

Athenex EPS beats by $0.13, beats on revenue

May 06

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Apr 04
Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Mar 09
Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06
These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19
Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29
When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Athenex. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

OTCPK:ATNX.Q Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 22103-984952
30 Sep 22123-1787056
30 Jun 22121-1927165
31 Mar 22109-1986771
31 Dec 2195-1585778
30 Sep 21113-1327578
30 Jun 21117-1358379
31 Mar 21137-1448680
31 Dec 20144-1429376
30 Sep 20157-1188479
30 Jun 20141-1167880
31 Mar 20123-10877101
31 Dec 19101-1236684
30 Sep 1988-1296065
30 Jun 1987-1415546
31 Mar 1977-145513
31 Dec 1889-11749120
30 Sep 1883-119500
30 Jun 1878-96490
31 Mar 1871-97490
31 Dec 1738-131462
30 Sep 1728-143440
30 Jun 1720-144400
31 Mar 1721-118310
31 Dec 1621-88260
30 Sep 1621-61210
31 Dec 1514-51260
31 Dec 141-1852

Ingresos de calidad: ATNX.Q is currently unprofitable.

Margen de beneficios creciente: ATNX.Q is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ATNX.Q is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Acelerando crecimiento: Unable to compare ATNX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: ATNX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Rentabilidad financiera

Alta ROE: ATNX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado